Taking adverse outcome pathways to the next level.
作者信息
Vinken Mathieu
机构信息
Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.
出版信息
Toxicol In Vitro. 2018 Aug;50:A1-A2. doi: 10.1016/j.tiv.2018.03.017. Epub 2018 Apr 6.
Abstract
摘要
相似文献
1
Taking adverse outcome pathways to the next level.
Toxicol In Vitro. 2018 Aug;50:A1-A2. doi: 10.1016/j.tiv.2018.03.017. Epub 2018 Apr 6.
2
Overview of neurotoxicology.神经毒理学概述。
Curr Protoc Toxicol. 2001 May;Chapter 11:Unit11.1. doi: 10.1002/0471140856.tx1101s06.
3
Correlating in vitro data to in vivo findings for risk assessment.将体外数据与体内发现相关联，以进行风险评估。
ALTEX. 2014;31(1):79-90. doi: 10.14573/altex.1310011. Epub 2013 Nov 14.
4
Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing.不良结局途径作为肝毒性测试中的多功能工具。
Methods Mol Biol. 2022;2425:521-535. doi: 10.1007/978-1-0716-1960-5_20.
5
Differentiating Pathway-Specific From Nonspecific Effects in High-Throughput Toxicity Data: A Foundation for Prioritizing Adverse Outcome Pathway Development.区分高通量毒性数据中的特异性途径与非特异性效应：优先开发不良结局途径的基础。
Toxicol Sci. 2018 Jun 1;163(2):500-515. doi: 10.1093/toxsci/kfy049.
6
Today's requirements in food, drug and chemical control.
Acta Pharmacol Toxicol (Copenh). 1983;52 Suppl 2:201-28. doi: 10.1111/j.1600-0773.1983.tb02691.x.
7
Biokinetic modeling and in vitro-in vivo extrapolations.生物动力学建模和体外-体内推断。
J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):242-52. doi: 10.1080/10937404.2010.483940.
8
Allometric models for interspecies extrapolation of wildlife toxicity data.用于野生动物毒性数据种间外推的异速生长模型。
Bull Environ Contam Toxicol. 1999 Jun;62(6):653-63. doi: 10.1007/s001289900924.
9
Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.作为评估药物诱导毒性工具的不良结局途径
Methods Mol Biol. 2016;1425:325-37. doi: 10.1007/978-1-4939-3609-0_14.
10
Virtual tissues in toxicology.虚拟组织在毒理学中的应用。
J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):314-28. doi: 10.1080/10937404.2010.483948.
引用本文的文献
1
An Adverse Outcome Pathway for food nanomaterial-induced intestinal barrier disruption.食品纳米材料诱导肠道屏障破坏的不良结局途径。
Front Toxicol. 2024 Dec 24;6:1474397. doi: 10.3389/ftox.2024.1474397. eCollection 2024.
2
Comprehensive mapping of the AOP-Wiki database: identifying biological and disease gaps.AOP-Wiki数据库的全面映射：识别生物学和疾病方面的差距。
Front Toxicol. 2024 Mar 8;6:1285768. doi: 10.3389/ftox.2024.1285768. eCollection 2024.
3
Particle Safety Assessment in Additive Manufacturing: From Exposure Risks to Advanced Toxicology Testing.增材制造中的颗粒安全性评估：从暴露风险到先进的毒理学测试
Front Toxicol. 2022 Apr 25;4:836447. doi: 10.3389/ftox.2022.836447. eCollection 2022.
4
Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.不良结局途径作为一种工具，用于设计测试策略，以支持纳米级新兴先进材料的安全性评估。
Part Fibre Toxicol. 2020 May 25;17(1):16. doi: 10.1186/s12989-020-00344-4.
5
Integration of epidemiological findings with mechanistic evidence in regulatory pesticide risk assessment: EFSA experiences.将流行病学研究结果与监管农药风险评估中的机制证据相结合：EFSA 的经验。
Arch Toxicol. 2019 Jun;93(6):1779-1788. doi: 10.1007/s00204-019-02467-w. Epub 2019 May 3.
本文引用的文献
1
Adverse outcome pathways: opportunities, limitations and open questions.不良结局途径：机遇、局限性和未解决问题。
Arch Toxicol. 2017 Nov;91(11):3477-3505. doi: 10.1007/s00204-017-2045-3. Epub 2017 Oct 19.
2
Adverse outcome pathways: a concise introduction for toxicologists.不良结局途径：毒理学家简明指南。
Arch Toxicol. 2017 Nov;91(11):3697-3707. doi: 10.1007/s00204-017-2020-z. Epub 2017 Jun 28.
3
The adverse outcome pathway concept: A basis for developing regulatory decision-making tools.不良结局途径概念：开发监管决策工具的基础。
Altern Lab Anim. 2016 Oct;44(5):417-429. doi: 10.1177/026119291604400504.
4
Adverse Outcome Pathways-Organizing Toxicological Information to Improve Decision Making.不良结局途径——组织毒理学信息以改善决策制定。
J Pharmacol Exp Ther. 2016 Jan;356(1):170-81. doi: 10.1124/jpet.115.228239. Epub 2015 Nov 4.
5
Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence.监管应用中的不良后果途径：对四个不同完整性和科学可信度案例研究的考察
Toxicol Sci. 2015 Nov;148(1):14-25. doi: 10.1093/toxsci/kfv181.
6
The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways.识别与肝脂肪变性相关的核受体，以建立和扩展不良结局途径。
Crit Rev Toxicol. 2016 Feb;46(2):138-52. doi: 10.3109/10408444.2015.1089471. Epub 2015 Oct 9.
7
Adverse Outcome Pathways can drive non-animal approaches for safety assessment.不良结局途径可推动用于安全性评估的非动物方法。
J Appl Toxicol. 2015 Sep;35(9):971-5. doi: 10.1002/jat.3165. Epub 2015 May 5.
8
Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.增强对不良结局途径的科学信心：运用定制的布拉德福德-希尔考量因素评估证据权重
Regul Toxicol Pharmacol. 2015 Aug;72(3):514-37. doi: 10.1016/j.yrtph.2015.04.004. Epub 2015 Apr 8.
9
Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes.提出一个科学置信度框架，以帮助支持将不良结局途径用于监管目的。
Regul Toxicol Pharmacol. 2015 Apr;71(3):463-77. doi: 10.1016/j.yrtph.2015.02.011. Epub 2015 Feb 20.
10
Adverse outcome pathway development II: best practices.不良结局途径的发展II：最佳实践。
Toxicol Sci. 2014 Dec;142(2):321-30. doi: 10.1093/toxsci/kfu200.
Zotero 插件